IL28B polymorphism,Explanation for Different Responses to Therapy in Hepatitis C Patients

AUTHORS

Heidar Sharafi 1 , Seyed Moayed Alavian ORCID 2 , *

1 Armin Pathobiology Laboratory, IR Iran

2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, [email protected], IR Iran

How to Cite: Sharafi H, Alavian S. IL28B polymorphism,Explanation for Different Responses to Therapy in Hepatitis C Patients, Hepat Mon. Online ahead of Print ; 11(12):958-959. doi: 10.5812/kowsar.1735143X.794.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (12); 958-959
Article Type: Editorial
Received: December 6, 2011
Accepted: December 30, 2011
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Implication for health policy/practice/research/medical education:
This article focuses on impact of IL28B polymorphisms on hepatitis C outcomes. This study is recommended to clinicians and researchers in the field of viral hepatitis.

Please cite this paper as:
Sharafi H, Alavian SM. IL28B polymorphism, explanation for Different Responses to Therapy in Hepatitis C patients. Hepat
Mon. 2011; 11(12):958-9. DoI: 10.5812/kowsar.1735143X.794

Full Text

Full text is available in PDF

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: